The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Nammi Therapeutics’ lead immunotherapy candidate QXL138AM…
Articles by Marta Figueiredo, PhD
Researchers in Japan have identified an antibody that binds to a myeloma-specific form of a common cell surface protein,…
Even if they’re fully vaccinated, multiple myeloma patients still have an increased risk of COVID-19 infection compared with people…
The U.S. Food and Drug Administration (FDA) has given fast track designation to Harpoon Therapeutics’ HPN217 as a potential immunotherapy…
The U.S. Food and Drug Administration (FDA) has approved the CAR T-cell therapy Carvykti (ciltacabtagene autoleucel) — formerly known…
Japan’s Ministry of Health, Labour, and Welfare has approved Abecma (idecabtagene vicleucel) as its first CAR T-cell therapy for…
Janssen is seeking the approval of its investigational therapy teclistamab in the U.S. for people with relapsed or refractory…
China’s National Medical Products Administration (NMPA) has conditionally approved a combination of Xpovio (selinexor) and the corticosteroid dexamethasone to…
The optimal dosing of tasquinimod, Active Biotech’s experimental oral therapy for adults with relapsed or refractory multiple myeloma,…
After promising early results, a sub-study of the DREAMM-5 platform trial is moving forward to its next phase to test…